[Ewing's sarcoma: therapeutic experience (author's transl)].
Since 1978, four patients with Ewing's sarcoma have been on a treatment-regimen based on the T-6 and T-2 Protocols according to Rosen. Preoperative chemotherapy produced tumor regression and thus enabled surgical resection in three cases. In the first case, radiation therapy was felt necessary because the surgical resection was performed after the first course of the T-6 Protocol and cells suspected to be malignant were found on histological examination of the resected tumor. The experience prompted us to refrain from using radiation therapy in the next two cases but to conduct the surgical resection after two cycles of T-6 Protocol. Here, histological examinations of the resected tumors showed no evidence of malignant cells. The fourth patient had a pathologic fracture in addition to the tumor. In this case, it was possible, by means of chemotherapy to heal the fracture and also to produce a regression of the tumor. Because of the radiation morbidity, we believe that it is a notable progress in the treatment of Ewing's sarcoma if radiation therapy can be avoided.
D000293:Adolescent; D001761:Bleomycin / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011300:Preoperative Care; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000601:surgery; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide; D008727:Methotrexate
Ewing Sarkom: Therapeutische Erfahrung.